Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats. Its numerous drug pricing provisions will likely undergo changes prior to
Read More »Articles by : Ron Shinkman,
Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.
“By empowering Medicare
Read More »Sectyr, an established provider of compliance platforms for 340B covered entities, has acquired LicenseTrak, a system for managing license, contract, training, and other business tasks, the companies announced last week.
Scottsdale, Ariz.-based Sectyr will fold Bloomington, Minn.-based LicenseTrak into its
Read More »UPDATE Tuesday, Oct. 26, 2021, 5:00 p.m. EDT—We have updated this article to reflect new information from the California Department of Health Care Services (DHCS) about the timeframe for the U.S. Centers for Medicare & Medicaid Services (CMS) to complete
Read More »If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes
Read More »The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services
Read More »Hundreds of family planning clinics that lost their Title X federal grants and 340B eligibility because they opposed a Trump-era rule barring them from providing abortion referrals might return to Title X and 340B soon.
The U.S. Department of Health
Read More »340B covered entities are exploring buying health insurance for patients at risk of contracting HIV in response to a huge reimbursement cut due to start in January for Gilead pre-exposure prophylaxis (PrEP) medications.
Gilead announced in April that, effective
Read More »Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.
Reps. Robin Kelly (D-Ill.) and Lisa
Read More »A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
The study by health economics and public health researchers at the University of California at Berkeley found that prices paid
Read More »